Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

October 29, 2019

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

October 24, 2019

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

October 23, 2019

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

October 17, 2019

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer.

October 14, 2019

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

October 11, 2019

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

October 10, 2019

Wallace L. Akerley, MD, discusses targeted approaches for patients with non-small cell lung cancer who harbor alterations in MET, RET, and HER2, as well as the importance of broad molecular profiling.

October 07, 2019

Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.

May 17, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses patient selection in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

April 19, 2019

Neeraj Agarwal, MD, professor of medicine, physician and investigator, director, Genitourinary Oncology Program, Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the updated results of the JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

April 17, 2019

Neeraj Agarwal, MD, discusses the recent encouraging data reported in mRCC and highlighted the next steps needed to move the needle forward in this space.

April 08, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

March 13, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the combination of lenvatinib (Lenvima) and everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

February 23, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

January 31, 2019

Neeraj Agarwal, MD, discusses his preferred sequencing strategies in the treatment of patients with mRCC.

January 04, 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

September 05, 2018

Benjamin L. Maughan, MD, PharmD, discusses the tolerability of combining radium-223 dichloride and enzalutamide, as well as the next steps with this combination.

August 14, 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.

July 20, 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging therapeutic techniques in bladder cancer.

July 18, 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.